[1] |
Katz, P.O.; Gerson, L.B.; Vela, M.F. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am. J. Gastroenterol. 2013, 108, 308–328.
|
[2] |
Iwakiri, K.; Kinoshita, Y.; Habu, Y.; Oshima, T.; Manabe, N.; Fujiwara, Y.; Nagahara, A.; Kawamura, O.; Iwakiri, R.; Ozawa, S.; Ashida, K.; Ohara, S.; Kashiwagi, H.; Adachi, K.; Higuchi, K.; Miwa, H.; Fujimoto, K.; Kusano, M.; Hoshihara, Y.; Kawano, T.; Haruma, K.; Hongo, M.; Sugano, K.; Watanabe, M.; Shimosegawa, T. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J. Gastroenterol. 2016, 51, 751–767.
|
[3] |
El-Serag, H.B.; Sweet, S.; Winchester, C.C.; Dent, J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014, 63, 871–880.
|
[4] |
Mermelstein, J.; Chait Mermelstein, A.; Chait, M.M. Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions. Clin. Exp. Gastroenterol. 2018, 11, 119–134.
|
[5] |
Wang, Y.P.; Ji, L.S.; Ni, M.; Fan, H.W.; Sha, J.P. Clinical effects of esomeprazole combined with mosapride for treatment of gastroesophageal reflux disease. World Chin. J. Dig. 2014, 22, 5671.
|
[6] |
Wu, Q.Y. Rabeprazole combined with trimebutine for treatment of patients with gastroesophageal reflux cough: Clinical efficacy and impact on serum levels of motilin and gastrin. World Chin. J. Dig. 2018, 26, 418.
|
[7] |
Cho, Y.K.; Choi, M.G.; Park, E.Y.; Lim, C.H.; Kim, J.S.; Park, J.M.; Lee, I.S.; Kim, S.W.; Choi, K.Y. Effect of mosapride combined with esomeprazole improves esophageal peristaltic function in patients with gastroesophageal reflux disease: a study using high resolution manometry. Dig. Dis. Sci. 2013, 58, 1035–1041.
|
[8] |
van Rensburg, C.J.; Bardhan, K.D. No clinical benefit of adding cisapride to pantoprazole for treatment of gastro-oesophageal reflux disease. Eur. J. Gastroenterol. Hepatol. 2001, 13, 909–914.
|
[9] |
Hsu, Y.C.; Yang, T.H.; Hsu, W.L.; Wu, H.T.; Cheng, Y.C.; Chiang, M.F.; Wang, C.S.; Lin, H.J. Mosapride as an adjunct to lansoprazole for symptom relief of reflux oesophagitis. Br. J. Clin. Pharmacol. 2010, 70, 171–179.
|
[10] |
Higgins, J.P.; Green, S. Cochrane handbook for systematic reviews of interventions. Chichester, UK: John Wiley & Sons, Ltd, 2008.
|
[11] |
Ndraha, S. Combination of PPI with a prokinetic drug in gastroesophageal reflux disease. Acta Med. Indonesiana. 2011, 43, 233–236.
|
[12] |
Miwa, H.; Inoue, K.; Ashida, K.; Kogawa, T.; Nagahara, A.; Yoshida, S.; Tano, N.; Yamazaki, Y.; Wada, T.; Asaoka, D.; Fujita, T.; Tanaka, J.; Shimatani, T.; Manabe, N.; Oshima, T.; Haruma, K.; Azuma, T.; Yokoyama, T. Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease - a double-blind, placebo-controlled study. Aliment. Pharmacol. Ther. 2011, 33, 323–332.
|
[13] |
Lee, J.Y.; Kim, S.K.; Cho, K.B.; Park, K.S.; Kwon, J.G.; Jung, J.T.; Kim, E.Y.; Jang, B.I.; Lee, S.H. A double-blind, randomized, multicenter clinical trial investigating the efficacy and safety of esomeprazole single therapy versus mosapride and esomeprazole combined therapy in patients with esophageal reflux disease. J. Neurogastroenterol. Motil. 2017, 23, 218–228.
|
[14] |
Madan, K.; Ahuja, V.; Kashyap, P.C.; Sharma, M.P. Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. Dis. Esophagus. 2004, 17, 274–278.
|
[15] |
Marakhouski, K.Y.; Karaseva, G.A.; Ulasivich, D.N.; Kh Marakhouski, Y. Omeprazole-domperidone fixed dose combination vs omeprazole monotherapy: a phase 4, open-label, comparative, parallel randomized controlled study in mild to moderate gastroesophageal reflux disease. Clin. Med. Insights: Gastroenterol. 2017.https://doi.org/10.1177/1179552217709456
|
[16] |
Yamaji, Y.; Isomura, Y.; Yoshida, S.; Yamada, A.; Hirata, Y.; Koike, K. Randomized controlled trial comparing the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in gastroesophageal reflux disease. J. Dig. Dis. 2014, 15, 469-476.
|
[17] |
Sharma, B.; Sharma, M.; Daga, M.K.; Sachdev, G.K.; Bondi, E. Effect of omeprazole and domperidone on adult asthmatics with gastroesophageal reflux. World J. Gastroenterol. 2007, 13, 1706–1710.
|
[18] |
Vigneri, S.; Termini, R.; Leandro, G.; Badalamenti, S.; Pantalena, M.; Savarino, V.; Di Mario, F.; Battaglia, G.; Mela, G.S.; Pilotto, A. A comparison of five maintenance therapies for reflux esophagitis. N. Engl. J. Med. 1995, 333, 1106–1110.
|
[19] |
Iwakiri, K.; Kawami, N.; Sano, H.; Tanaka, Y.; Umezawa, M.; Kotoyori, M.; Hoshihara, Y.; Sakamoto, C. Mechanisms of excessive esophageal acid exposure in patients with reflux esophagitis. Dig. Dis. Sci. 2009, 54, 1686–1692.
|
[20] |
Acosta, A.; Camilleri, M. Prokinetics in gastroparesis. Gastroenterol. Clin. N. Am. 2015, 44, 97–111.
|
[21] |
Chang, P.; Friedenberg, F. Obesity and gerd. Gastroenterol. Clin. N. Am. 2014, 43, 161–173.
|
[22] |
Ren, L.H.; Chen, W.X.; Qian, L.J.; Li, S.; Gu, M.; Shi, R.H. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis. World J. Gastroenterol. 2014, 20, 2412–2419.
|
[23] |
Liu, Q.; Feng, C.C.; Wang, E.M.; Yan, X.J.; Chen, S.L. Efficacy of mosapride plus proton pump inhibitors for treatment of gastroesophageal reflux disease: a systematic review. World J. Gastroenterol. 2013, 19, 9111–9118.
|
[24] |
Li, M.J.; Li, Q.; Sun, M.; Liu, L.Q. Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: a PRISMA-compliant network meta-analysis. Medicine (Baltimore). 2017, 96, e8120.
|
[25] |
Chen, L.X.; Chen, Y.J.; Li, B. The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis. Sci. Rep. 2016, 6, 32126.
|
[26] |
Jarosz, M.; Taraszewska, A. Risk factors for gastroesophageal reflux disease - the role of diet. Gastroenterol. Rev. 2014, 5, 297–301.
|